Basilea Pharmaceutica Acquires Spexis’ Preclinical Antibiotics Program for $2.34M

Share this


Basilea Pharmaceutica Acquires Spexis’ Preclinical Antibiotics Program for $2.34M


  • Basilea Pharmaceutica and Spexis have signed an asset purchase agreement for preclinical antibiotics program focusing on gram-negative bacteria, incl. novel multidrug-resistant strains
  • As per the agreement, Basilea acquires all program compounds, know-how, and intellectual property from Spexis for a total payment of $2.34M (CHF 2M) which includes an up front payment, a transfer-related payment, and a potential final milestone payment linked to near-term external funding for the program's development
  • Additionally, Basilea also takes over Spexis' rights and obligations, incl. potential low single-digit percentage royalties on sales through licensing agreements

Ref: Basilea | Image: Basilea

Related News:- Basilea Announces the US FDA Approval of Cresemba (isavuconazole) in Pediatric Patients to Treat Invasive Aspergillosis & Invasive Mucormycosis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions